Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, Open-Label, Single-Arm, Dose-Escalation, Investigator-Initiated Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of an In Vivo Circular RNA Chimeric Antigen Receptor (CAR) T Cell Therapy in Adult Participants With Relapsed or Refractory B-Cell Malignancies

NCT07774572 is registered in ClinicalTrials.gov with Ruijin Hospital as lead sponsor.

NCT NCT07774572
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07774572 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, Open-Label, Single-Arm, Dose-Escalation, Investigator-Initiated Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of an In Vivo Circular RNA Chimeric Antigen Receptor (CAR) T Cell Therapy in Adult Participants With Relapsed or Refractory B-Cell Malignancies
Lead sponsor
Ruijin Hospital
Phase
Phase 1
Overall status
Recruiting
Start date
May 26, 2026
Completion date
March 31, 2029
Enrollment
30 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

lymphoma, b-cell refractory